UTILIZING MULTI-PARAMETER MAGNETIC RESONANCE IMAGING AND GUIDED BIOPSY FOR EARLY DETECTION OF PROSTATE CANCER: IMPLICATIONS FOR ATHLETE HEALTH MONITORING

Abstract

Objective: To evaluate the diagnostic accuracy of multi-parameter magnetic resonance imaging (mpMRI) and mpMRI-guided biopsy in detecting prostate cancer, emphasizing its potential role in health monitoring for athletes. Methods: Eighty patients with suspected prostate cancer treated at our hospital from January 2021 to January 2023 underwent mpMRI-guided biopsy, followed by histopathological evaluation. If pathology results were inconclusive, CT-guided biopsy was performed as needed. The diagnostic efficiency of mpMRI and mpMRI-guided biopsy was assessed based on accuracy, sensitivity, and specificity, using histopathological findings as the gold standard. Procedure-related complications were also recorded and analyzed. Results: Among 80 suspected cases, 79 were confirmed with prostate cancer, including various histological subtypes such as adenocarcinoma, ductal adenocarcinoma, and squamous cell carcinoma. The accuracy, sensitivity, and specificity of mpMRI-guided biopsy were 96.25%, 97.46%, and 100.00%, respectively. In contrast, mpMRI alone showed an accuracy of 62.5%, sensitivity of 96.15%, and specificity of 17.85%. The differences in diagnostic performance were statistically significant (P < 0.05). Moreover, the procedure was well-tolerated, with only three patients experiencing mild infection-related complications. Conclusion: mpMRI-guided biopsy outperforms mpMRI alone in diagnosing prostate cancer, offering superior accuracy, sensitivity, and specificity with minimal complications. Its application could extend to athlete health screening programs, where early detection and monitoring of prostate conditions are critical for maintaining peak physical performance.